Abstract
The differences in diagnosis and management between immune thrombocytopenia (ITP) and leukemia are striking. Leukemia diagnosis and management have evolved substantially over the past 30 years and are now relatively precise. The tendency for leukemic cells to be the overwhelming majority of circulating and/or bone marrow cells certainly continues to facilitate developments, as does improved molecular assessment. Furthermore, randomized controlled clinical trials of competing regimens in well-defined populations have advanced treatment as well. Currently, ITP diagnosis and management depend very much on the experience and preferences of the hematologist. There are no unequivocally useful molecular tests, no agreement on which testing needs to be performed, and no consensus on treatment. Future studies using advanced techniques would ideally change this over time but, thus far, progress in ITP has been slow. However, the increasing ability to do single-cell DNA and RNA studies and flow cytometric dissection of small populations of cells could radically change the approach to ITP if critical distinctions were uncovered.
Article PDF
Avoid common mistakes on your manuscript.
References
Bennett, JM, Catovsky, D, Daniel, MT, Flandrin, G, Galton, DA, Gralnick, HR, Sultan, C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33;451–8.
Tasian, SK, Loh, ML, Hunger, SP. Childhood acute lymphoblastic leukemia: integrating genomics into therapy. Cancer 2015;121; 3577–90.
Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, Bloomfield, CD, Cazzola, M, Vardiman, JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127; 2391–405.
Taylor, J, Xiao, W, Abdel-Wahab, O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 2017;130;410–23.
Stone, RM, Mandrekar, SJ, Sanford, BL, Laumann, K, Geyer, S, Bloomfield, CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377;454–64.
Antar, A, Otrock, ZK, El-Cheikh, J, Kharfan-Dabaja, MA, Battipaglia, G, Mahfouz, R, Mohty, M, Bazarbachi, A. Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant 2017;52;344–51.
Stein, EM, DiNardo, CD, Pollyea, DA, Fathi, AT, Roboz, GJ, Altman, JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130;722–31.
DiNardo, CD, Stein, EM, de Botton, S, Roboz, GJ, Altman, JK, Mims, AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378; 2386–98.
El Fakih, R, Jabbour, E, Ravandi, F, Hassanein, M, Anjum, F, Ahmed, S, Kantarjian, H. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol 2018;93;286–95.
Druker, BJ, Sawyers, CL, Kantarjian, H, Resta, DJ, Reese, SF, Ford, JM, Capdeville, R, Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344; 1038–42.
Steinberg, M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007;29;2289–308.
Wang, ZY, Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111;2505–15.
Neunert, C, Lim, W, Crowther, M, Cohen, A, Solberg Jr, L, Crowther, MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117;4190–207.
Kelton, JG, Vrbensky, JR, Arnold, DM. How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program 2018;2018;561–7.
Cunningham-Rundles, C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008; 28: S42–S5.
Gobert, D, Bussel, JB, Cunningham-Rundles, C, Galicier, L, Dechartres, A, Berezne, A, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011;155;498–508.
DiMaggio,D,Anderson, A,Bussel, JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol 2009;146;104–12.
Canale, VC, Smith, CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967;70;891–9.
Cines, DB, Bussel, JB, Liebman, HA, Luning Prak, ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113; 6511–21.
Aster, RH, Bougie, DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357;580–7.
Mithoowani, S, Gregory-Miller, K, Goy, J, Miller, MC, Wang, G, Noroozi, N, Kelton, JG, Arnold, DM. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2016;3;e489–e96.
Mazzucconi, MG, Fazi, P, Bernasconi S, De Rossi, G, Leone, G, Gugliotta, L, et al. Gruppo Italiano Malattie EdATWP. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007;109; 1401–7.
Bussel, J, Arnold, DM, Grossbard, E, Mayer, J, Trelinski, J, Homenda, W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018; 93;921–30.
Bussel, JB, de Miguel, PG, Despotovic, JM, Grainger, JD, Sevilla, J, Blanchette, VS, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2015;2;e315–e25.
Ghanima, W, Khelif, A, Waage, A, Michel, M, Tjonnfjord, GE, Romdhan, NB, Kahrs, J, Darne, B, Holme, PA, RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;385;1653–61.
Ghanima, W, Cooper, N, Rodeghiero, F, Godeau, B, Bussel, JB. Thrombopoietin receptor agonists: ten years later. Haematologica 2019;104;1112–23.
Chapin, J, Lee, CS, Zhang, H, Zehnder, JL, Bussel, JB. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol 2016;91;907–11.
Oved, JH, Lee, CSY, Bussel, JB. Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone. J Pediatr 2017;191;225–31.
Fallah, M, Liu, X, Ji, J, Forsti, A, Sundquist, K, Hemminki, K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 2014;25;2025–30.
Rodeghiero, F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 2018;181;183–95.
King, H, Shumacker Jr, HB. Splenic studies. I. Susceptibility to infection after splenectomy performed in infancy. Ann Surg 1952; 136;239–42.
Chaturvedi, S, Arnold, DM, McCrae, KR. Splenectomy for immune thrombocytopenia: down but not out. Blood 2018;131; 1172–82.
Rorholt, M, Ghanima, W, Farkas, DK, Norgaard, M. Risk of cardiovascular events and pulmonary hypertension following splenectomy—a Danish population-based cohort study from 1996–2012. Haematologica 2017;102;1333–41.
Bussel, JB, Arnold, DM, Boxer, MA, Cooper, N, Mayer, J, Zayed, H, Tong, S, Duliege, AM. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol 2019;94;546–53.
Mihova, D. Acute myeloid leukemia without maturation (FAB AML M1), 2013. http://www.pathologyoutlines.com/topic/leukemiaM1.html (accessed July 8, 2019).
Bennett, JM, Catovsky, D, Daniel, MT, Flandrin, G, Galton, DA, Gralnick, HR, Willman, CL. Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15; 17) and t(11; 17). Leukemia 2000; 14;1197–200.
Ichihashi, T, Naoe, T, Kuriyama, K, Sasada, M, Ohno, R. Acute myeloid leukemia, 1996. http://www3.med.unipmn.it/did/will/atlashem/node47.htm. Acute megakaryoblastic leukemia (AMKL) (M7) flow cytometry. http://wiki.clinicalflow.com/acute-megakaryoblastic-leukemia-amkl-m7 (accessed July 9, 2019).
Gedde-Dahl, T. Chronic myeloid leukemia, 2010. http://oncolex.org/imageViewer.aspx?OpenFromImageNavigator=true&imageItemID=%7B73B3F6CC-68A9-41C8-9F63-2183BD7F86CC%7D&procid=/sitecore/content/Home/Prosedyrer/DIAGNOSTIKK/Leukemi%20KML&image=/-/media/PROSEDYRER/DIAGNOSTIKK/Leukemi-KML/popups/kml.ashx (accessed July 9, 2019).
Stanley Medical College, Department of Medicine. Acute lym-phoblastic leukaemia. Health & Medicine presented at the: 11: 28:25 UTC, 2010. https://www.slideshare.net/smcmedicinedept/acute-lymphoblastic-leukaemia (accessed July 9, 2019).
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review is under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Bussel, J., Miltiadous, O. Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. Clin Hematol Int 1, 173–179 (2019). https://doi.org/10.2991/chi.d.190805.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190805.001